Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levodopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | LCK | P06239 | 1/20 | 0.69 |
| ▸ | FYN | P06241 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | KDM6B | O15054 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levodopa SCHEMBL20637810 | 1.00 | SLC7A5 (0.69) | SLC7A5PTGS1ALOX15KDM4EUSP2 | |
| Levodopa SCHEMBL20637809 | 1.00 | SLC7A5 (0.69) | SLC7A5PTGS1ALOX15KDM4EUSP2 | |
| Levodopa SCHEMBL27642065 | 0.89 | SLC7A5 (0.87) | SLC7A5PTGS1ALOX15KDM4EUSP2 | |
| Levodopa SCHEMBL896629 | 0.89 | SLC7A5 (0.87) | SLC7A5PTGS1ALOX15KDM4EUSP2 | |
| Dl-Phenylalanine SCHEMBL28481409 | 0.88 | SLC7A5 (0.73) | SLC7A5PTGS1ALOX15KDM4EHIF1A | |
| Dl-Phenylalanine SCHEMBL28169117 | 0.88 | SLC7A5 (0.73) | SLC7A5PTGS1ALOX15KDM4EHIF1A | |
| Tyrosine SCHEMBL4908261 | 0.87 | SLC7A5 (0.69) | SLC7A5PTGS1ALOX15KDM4EUSP2 | |
| SCHEMBL29913698 | 0.86 | KDM6B (0.62) | SLC7A5PTGS1ALOX15KDM4EUSP2 | |
| Levodopa SCHEMBL8579019 | 0.85 | SLC7A5 (0.79) | SLC7A5PTGS1ALOX15KDM4EUSP2 | |
| Levodopa SCHEMBL8579024 | 0.85 | SLC7A5 (0.79) | SLC7A5PTGS1ALOX15KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1958651-B1 | Viable tissue repair implants | DEPUY MITEK INC (US) | 2011-10-12 | — | — | EP | claimed |
| EP-2101681-B1 | METHOD OF OBTAINING VIABLE SMALL TISSUE PARTICLES AND USE FOR TISSUE REPAIR | ZIMMER ORTHOBIOLOGICS INC (US) | 2011-08-03 | — | — | EP | claimed |
| US-7875296-B2 | Injectable suspension of a tissue carrier matrix of biocompatible,bioresorbable granules and a tissue fragment containing viable cells that migrate from the tissue and populate the matrix; rotator cuff injuries, ACL ruptures, and meniscal tears | DEPUY MITEK, INC. (US) | 2011-01-25 | — | — | US | claimed |
| JP-6157251-A | — | — | None | — | — | JP | disclosed |
| US-20230372313-A1 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | GENZYME CORPORATION | 2023-11-23 | — | — | US | disclosed |
| CN-116322679-A | Methods for reducing the concentration of glycosphingolipids in brain tissue and methods of treatment of neurodegenerative diseases involving reducing the concentration of glycosphingolipids in brain tissue | 建新公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4188381-A1 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | Genzyme Corporation (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022024062-A1 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | GENZYME CORPORATION (US) | 2022-02-03 | — | — | WO | disclosed |
| EP-3066207-A1 | BENZYLISOQUINOLINE ALKALOID (BIA) PRECURSOR PRODUCING MICROBES, AND METHODS OF MAKING AND USING THE SAME | The Board Of Trustees Of The University Of the Leland Stanford Junior University (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20150258220-A1 | MAGNETIC RESONANCE IMAGING AND/OR SPECTROSCOPY CONTRAST AGENTS AND METHODS OF USE THEREOF | UNIV DUKE (US) | 2015-09-17 | — | — | US | disclosed |
| WO-2015066642-A1 | BENZYLISOQUINOLINE ALKALOID (BIA) PRECURSOR PRODUCING MICROBES, AND METHODS OF MAKING AND USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-05-07 | — | — | WO | disclosed |
| US-20040016910-A1 | Non-toxic corrosion-protection rinses and seals based on rare earth elements | DAYTON, UNIVERSITY OF | 2004-01-29 | — | — | US | disclosed |
| EP-0841065-B1 | Use of sericin as antioxidants and tyrosinase inhibitors | SEIREN CO LTD (JP) | 2003-06-04 | — | — | EP | disclosed |
| EP-1290133-A1 | MODULAR APPROACH TO ON-LINE SYNTHESIS, DRUG DISCOVERY AND BIOCHEMICAL TRANSFORMATIONS USING IMMOBILIZED ENZYME REACTORS | McGill University (CA) | 2003-03-12 | — | — | EP | disclosed |
| EP-1246603-A1 | ORAL USE OF DEHYDROEPIANDROSTERONE AND SOME OF ITS DERIVATIVES AS PIGMENTATION REGULATORS | ASSISTANCE PUBLIQUE, HOPITAUX DE PARIS (FR) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001090298-A1 | MODULAR APPROACH TO ON-LINE SYNTHESIS, DRUG DISCOVERY AND BIOCHEMICAL TRANSFORMATIONS USING IMMOBILIZED ENZYME REACTORS | MCGILL UNIVERSITY (CA) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001051022-A1 | ORAL USE OF DEHYDROEPIANDROSTERONE AND SOME OF ITS DERIVATIVES AS PIGMENTATION REGULATORS | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2001-07-19 | — | — | WO | disclosed |
| CN-1270513-A | Use of at least one extract of Chrysanthemum for promoting skin and/or hair pigmentation | OREAL (FR) | 2000-10-18 | — | — | CN | disclosed |
| EP-0841065-A2 | Use of sericin as antioxidants and tyrosinase inhibitors | SEIREN CO., LTD. (JP) | 1998-05-13 | — | — | EP | disclosed |
| JP-H06157251-A | COSMETIC COMPOSITION | UNILEVER NV | 1994-06-03 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372313-A1 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | GBA1, GBA2, GALC | SLC7A5 717/4885PTGS1 3161/4885ALOX15 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.